Reticulohistiocytoma Overview

Save information for later
Sign Up

Learn About Reticulohistiocytoma

What is the definition of Reticulohistiocytoma?
Reticulohistiocytoma (RH) is a rare benign lesion of the soft tissue. It belongs to a group of disorders called non-Langerhans cell histiocytosis and is a type of reticulohistiocytosis, all of which are types of histiocytosis. Histiocytosis is a condition in which there is rapid production (proliferation) of histiocytes (immune cells) in the skin or soft tissues. The stimulus that causes the immune system to react in RH is currently not well understood. RH present as a yellow to reddish-brown smooth surfaced, firm nodule or lesion on the trunk and/or extremities of the body. Historically, RH has been found in young adults, with a slightly higher incidence in males.
What are the alternative names for Reticulohistiocytoma?
  • Reticulohistiocytoma
  • Solitary histiocytoma
  • Solitary reticulohistiocytosis
Who are the top Reticulohistiocytoma Local Doctors?
Jithma P. Abeykoon
Elite in Reticulohistiocytoma
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology
Elite in Reticulohistiocytoma
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jithma Abeykoon is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Abeykoon and is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Waldenstrom Macroglobulinemia, Histiocytosis, Reticulohistiocytoma, Tissue Biopsy, and Bone Marrow Transplant. Dr. Abeykoon is currently accepting new patients.

Elite in Reticulohistiocytoma
J J. Haroche
Elite in Reticulohistiocytoma
J J. Haroche
Paris, FR 

J Haroche practices in Paris, France. Haroche and is rated as an Elite expert by MediFind in the treatment of Reticulohistiocytoma. Their top areas of expertise are Erdheim-Chester Disease, Histiocytosis, Reticulohistiocytoma, Non-Langerhans-Cell Histiocytosis, and Tissue Biopsy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Reticulohistiocytoma
Dr. Carl E. Allen
Pediatric Hematology Oncology
Elite in Reticulohistiocytoma
Dr. Carl E. Allen
Pediatric Hematology Oncology
6701 Fannin St, 
Houston, TX 
832-822-4890
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Allen is a Pediatric Hematologist Oncology provider in Houston, Texas. Dr. Allen and is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant. Dr. Allen is currently accepting new patients.

View All Doctors
What are the latest Reticulohistiocytoma Clinical Trials?
A Real-world Investigation of the Combination of Darafenib or Trametinib and Clofarabine in the Treatment of High-risk, Recurrent, or Refractory Pediatric Patients With Langerhans Cell Histiocytosis.
A Real-world Investigation of the Combination of Darafenib or Trametinib and Clofarabine in the Treatment of High-risk, Recurrent, or Refractory Pediatric Patients With Langerhans Cell Histiocytosis.
Enrollment Status: Recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: Langerhans cell histiocytosis (LCH) is the most common histiocytosis in children, with an incidence of 2.6-8.9 per million. It is an inflammatory myeloid tumor with varied symptoms. Mild cases often resolve spontaneously, while severe cases can affect multiple organs and be life-threatening. LCH affecting the liver, spleen, or hematopoietic system has a poor prognosis and is high-risk group. The L...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Enrollment Status: Recruiting
Publish Date: June 15, 2025

Summary: This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a genetic disorder that results in progressive loss of nervous system function. The study will: 1) look for a clinical or biochemical marker that can be used as a measure of response to treatment, and 2) define the rat...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center